Filed by Flex Pharma, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
under the Securities Exchange Act of 1934
Subject Company: Salarius Pharmaceuticals, LLC
SEC File No.:
Flex Pharma, Inc. intends to send the following letter to certain of its stockholders.
June 19, 2019
YOUR VOTES ARE STILL NEEDEDEVERY VOTE COUNTS!
Dear Flex Shareholder:
Not enough shares have been voted for
us to complete our merger with Salarius Pharmaceuticals, LLC. Your fellow shareholders that have voted
overwhelmingly support the merger
. However, in order to consummate the merger, we need a quorum at our special meeting (which will be
reconvened on July 12) and our shareholders need to approve Proposals 1, 2 and 3, which are described in our proxy materials.
- That is
why we still need
you to vote your shares
The high level of support for the merger is consistent with the recommendations of both
leading, independent proxy advisory firms (Institutional Shareholder Services or ISS, and Glass Lewis) and our Board of Directors, which unanimously recommends voting FOR all agenda items as the best way to preserve future
- Time is running out! -
We will reconvene the special meeting on July 12, 2019, so there is no time to waste if you want to preserve the value of your shares.
Even if you do
not own Flex stock today, as a shareholder as of the record date (April 17), we still need your vote.
If we do not secure the needed votes, our planned merger with Salarius cannot take place. Your vote will help complete the merger, which will
support the development of potentially life-saving epigenetic therapies for cancer.
- Please vote your shares FOR the merger, today! -
You can vote FOR all agenda items by telephone, via the Internet or using the proxy card you received with your proxy materials. For
assistance in voting shares, or to receive additional copies of the proxy materials:
- Call Innisfree M&A Incorporated TODAY at
Your vote is
critically important. If we do not complete the merger, we will likely
wind-up, which could
cause shareholders to lose most of the value of their investment.
Thank you for taking the time to help.
Very truly yours,
William McVicar, Ph.D.
President and Chief Executive Officer